181 related articles for article (PubMed ID: 38413399)
1. Production of recombinant vesicular stomatitis virus-based vectors by tangential flow depth filtration.
Göbel S; Pelz L; Silva CAT; Brühlmann B; Hill C; Altomonte J; Kamen A; Reichl U; Genzel Y
Appl Microbiol Biotechnol; 2024 Feb; 108(1):240. PubMed ID: 38413399
[TBL] [Abstract][Full Text] [Related]
2. Process intensification strategies toward cell culture-based high-yield production of a fusogenic oncolytic virus.
Göbel S; Jaén KE; Dorn M; Neumeyer V; Jordan I; Sandig V; Reichl U; Altomonte J; Genzel Y
Biotechnol Bioeng; 2023 Sep; 120(9):2639-2657. PubMed ID: 36779302
[TBL] [Abstract][Full Text] [Related]
3. Production of retroviral vectors in continuous high cell density culture.
Hein MD; Kazenmaier D; van Heuvel Y; Dogra T; Cattaneo M; Kupke SY; Stitz J; Genzel Y; Reichl U
Appl Microbiol Biotechnol; 2023 Oct; 107(19):5947-5961. PubMed ID: 37542575
[TBL] [Abstract][Full Text] [Related]
4. A Novel Chimeric Oncolytic Virus Vector for Improved Safety and Efficacy as a Platform for the Treatment of Hepatocellular Carcinoma.
Abdullahi S; Jäkel M; Behrend SJ; Steiger K; Topping G; Krabbe T; Colombo A; Sandig V; Schiergens TS; Thasler WE; Werner J; Lichtenthaler SF; Schmid RM; Ebert O; Altomonte J
J Virol; 2018 Dec; 92(23):. PubMed ID: 30232179
[TBL] [Abstract][Full Text] [Related]
5. Cell culture-based production of defective interfering influenza A virus particles in perfusion mode using an alternating tangential flow filtration system.
Hein MD; Chawla A; Cattaneo M; Kupke SY; Genzel Y; Reichl U
Appl Microbiol Biotechnol; 2021 Oct; 105(19):7251-7264. PubMed ID: 34519855
[TBL] [Abstract][Full Text] [Related]
6. Enhanced oncolytic activity of vesicular stomatitis virus encoding SV5-F protein against prostate cancer.
Chang G; Xu S; Watanabe M; Jayakar HR; Whitt MA; Gingrich JR
J Urol; 2010 Apr; 183(4):1611-8. PubMed ID: 20172545
[TBL] [Abstract][Full Text] [Related]
7. High cell density cultivations by alternating tangential flow (ATF) perfusion for influenza A virus production using suspension cells.
Genzel Y; Vogel T; Buck J; Behrendt I; Ramirez DV; Schiedner G; Jordan I; Reichl U
Vaccine; 2014 May; 32(24):2770-81. PubMed ID: 24583003
[TBL] [Abstract][Full Text] [Related]
8. Retroviral vector production using suspension-adapted 293GPG cells in a 3L acoustic filter-based perfusion bioreactor.
Ghani K; Garnier A; Coelho H; Transfiguracion J; Trudel P; Kamen A
Biotechnol Bioeng; 2006 Nov; 95(4):653-60. PubMed ID: 16947907
[TBL] [Abstract][Full Text] [Related]
9. Bioreactor production of rVSV-based vectors in Vero cell suspension cultures.
Kiesslich S; Kim GN; Shen CF; Kang CY; Kamen AA
Biotechnol Bioeng; 2021 Jul; 118(7):2649-2659. PubMed ID: 33837958
[TBL] [Abstract][Full Text] [Related]
10. AAV process intensification by perfusion bioreaction and integrated clarification.
Mendes JP; Fernandes B; Pineda E; Kudugunti S; Bransby M; Gantier R; Peixoto C; Alves PM; Roldão A; Silva RJS
Front Bioeng Biotechnol; 2022; 10():1020174. PubMed ID: 36420444
[TBL] [Abstract][Full Text] [Related]
11. Bioreactors for high cell density and continuous multi-stage cultivations: options for process intensification in cell culture-based viral vaccine production.
Tapia F; Vázquez-Ramírez D; Genzel Y; Reichl U
Appl Microbiol Biotechnol; 2016 Mar; 100(5):2121-32. PubMed ID: 26758296
[TBL] [Abstract][Full Text] [Related]
12. Xenoantigen-Dependent Complement-Mediated Neutralization of Lymphocytic Choriomeningitis Virus Glycoprotein-Pseudotyped Vesicular Stomatitis Virus in Human Serum.
Pipperger L; Koske I; Wild N; Müllauer B; Krenn D; Stoiber H; Wollmann G; Kimpel J; von Laer D; Bánki Z
J Virol; 2019 Sep; 93(18):. PubMed ID: 31243134
[TBL] [Abstract][Full Text] [Related]
13. Interleukin-12 expression enhances vesicular stomatitis virus oncolytic therapy in murine squamous cell carcinoma.
Shin EJ; Wanna GB; Choi B; Aguila D; Ebert O; Genden EM; Woo SL
Laryngoscope; 2007 Feb; 117(2):210-4. PubMed ID: 17204993
[TBL] [Abstract][Full Text] [Related]
14. Current good manufacturing practice production of an oncolytic recombinant vesicular stomatitis viral vector for cancer treatment.
Ausubel LJ; Meseck M; Derecho I; Lopez P; Knoblauch C; McMahon R; Anderson J; Dunphy N; Quezada V; Khan R; Huang P; Dang W; Luo M; Hsu D; Woo SL; Couture L
Hum Gene Ther; 2011 Apr; 22(4):489-97. PubMed ID: 21083425
[TBL] [Abstract][Full Text] [Related]
15. Recombinant Isfahan Virus and Vesicular Stomatitis Virus Vaccine Vectors Provide Durable, Multivalent, Single-Dose Protection against Lethal Alphavirus Challenge.
Nasar F; Matassov D; Seymour RL; Latham T; Gorchakov RV; Nowak RM; Leal G; Hamm S; Eldridge JH; Tesh RB; Clarke DK; Weaver SC
J Virol; 2017 Apr; 91(8):. PubMed ID: 28148802
[TBL] [Abstract][Full Text] [Related]
16. Live virus vaccines based on a vesicular stomatitis virus (VSV) backbone: Standardized template with key considerations for a risk/benefit assessment.
Clarke DK; Hendry RM; Singh V; Rose JK; Seligman SJ; Klug B; Kochhar S; Mac LM; Carbery B; Chen RT;
Vaccine; 2016 Dec; 34(51):6597-6609. PubMed ID: 27395563
[TBL] [Abstract][Full Text] [Related]
17. Mucosal Delivery of Recombinant Vesicular Stomatitis Virus Vectors Expressing Envelope Proteins of Respiratory Syncytial Virus Induces Protective Immunity in Cotton Rats.
Binjawadagi B; Ma Y; Binjawadagi R; Brakel K; Harder O; Peeples M; Li J; Niewiesk S
J Virol; 2021 Feb; 95(6):. PubMed ID: 33408176
[TBL] [Abstract][Full Text] [Related]
18. Cell-line screening and process development for a fusogenic oncolytic virus in small-scale suspension cultures.
Göbel S; Kortum F; Chavez KJ; Jordan I; Sandig V; Reichl U; Altomonte J; Genzel Y
Appl Microbiol Biotechnol; 2022 Aug; 106(13-16):4945-4961. PubMed ID: 35767011
[TBL] [Abstract][Full Text] [Related]
19. mRNA cap methylation influences pathogenesis of vesicular stomatitis virus in vivo.
Ma Y; Wei Y; Zhang X; Zhang Y; Cai H; Zhu Y; Shilo K; Oglesbee M; Krakowka S; Whelan SP; Li J
J Virol; 2014 Mar; 88(5):2913-26. PubMed ID: 24371058
[TBL] [Abstract][Full Text] [Related]
20. Recombinant vesicular stomatitis virus as an HIV-1 vaccine vector.
Clarke DK; Cooper D; Egan MA; Hendry RM; Parks CL; Udem SA
Springer Semin Immunopathol; 2006 Nov; 28(3):239-53. PubMed ID: 16977404
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
